| Multiple Sclerosis |
1 |
1 |
| Child |
0 |
1 |
| Obesity |
0 |
0.76 |
| Adverse Effects |
0 |
0.25 |
| Patient Safety |
0 |
0.22 |
| Adherence |
0 |
0.17 |
| Adolescent Medicine |
0 |
0.17 |
| Disease-Modifying Therapy |
0 |
0.17 |
| Biologic Therapy |
0 |
0.14 |
| Arizona |
0 |
0.09 |
| California |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Glatiramer Acetate |
0 |
0.09 |
| Insurance |
0 |
0.09 |
| Interferon Beta |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Students |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Pregnancy |
0 |
0.07 |
| Revenue and Practice Management |
0 |
0.07 |